Why a 90‑day benefits cost reset works for 15–30‑employee teams

Small groups face the most volatility because a single high‑cost claim or fee‑guide change can swing renewal pricing. A focused 12‑week program can reset plan design, funding, and vendor terms in time for your next renewal, while preserving member value.

• Audience: Canadian employers with 15–30 employees (non‑union, or where plan design can be amended outside collective bargaining).

• Objective: Neutralize 2025 trend pressure and reduce total plan cost without eroding perceived value.

• Method: Phased actions, evidence‑based drug controls, correct pooling/stop‑loss thresholds, and disciplined quoting.

90‑day plan and deliverables

Weeks 0–2: Baseline, leakage control, RFP prep

• Extract 24 months of claims by category (drug, dental, EHC, out‑of‑country), top molecules, specialty vs. traditional, and dispensing frequency.

• Collect contracts, booklets, experience reports, current pooling/stop‑loss riders, and fee schedules.

• Immediate no‑friction switches (typically implementable mid‑term):

• Activate mandatory generic substitution; confirm biosimilar substitution language and prior authorization for targeted biologics.

• Align pharmacy dispensing to 90‑day maintenance fills and cap dispensing fees/compounding fees per script.

• Standardize coordination‑of‑benefits and reasonable‑and‑customary limits for paramedicals.

• Issue market‑wide RFP: pooled insured vs. experience‑rated vs. ASO (with stop‑loss). Request EP3 and industry‑pooling details, and stop‑loss quotes at multiple attachment points.

Weeks 2–6: Design decisions and carrier selection

• Choose funding method by volatility tolerance and claims profile (see ASO vs. insured comparison below).

• Set drug‑plan controls: managed formulary with prior auth for high‑cost therapies; biosimilar first‑line or switch; specialty pharmacy channeling.

• Tune dental: reimburse at current‑year fee guide, require predeterminations > set thresholds, and restrict frequency limits for high‑cost procedures.

• Fix catastrophic protection:

• Fully insured: verify EP3 pooling level and industry pooling rules.

• ASO: purchase individual stop‑loss at the right threshold for your size and claims pattern.

• Award business, complete binder‑of‑record, and lock installation timeline.

Weeks 6–12: Implementation and member communications

• Member‑first rollout: clear drug‑switch and dental‑fee communications; emphasize no‑disruption maintenance drug refills and equivalents.

• Payroll and HRIS: update taxable benefit flags, waiting periods, and eligibility rules.

• Governance artifacts: finalize booklets, pooling/stop‑loss exhibits, and prior‑authorization lists. Calendar quarterly utilization reviews.

Drug‑plan controls that reduce spend (2025‑ready)

• Biosimilars: Health Canada states no meaningful clinical differences are expected when switching between a reference biologic and a biosimilar in an authorized indication. Provinces continue to expand biosimilar switching in public programs, accelerating private‑plan adoption.

• High‑cost drug dynamics: Private plans saw specialty drugs represent ~33% of eligible private drug spend in 2024, with ultra‑high‑cost therapies (e.g., cystic fibrosis) materially impacting trend; expect continued pressure through 2026.

• Practical controls to implement in 90 days:

• Prior authorization and case management for targeted biologics and GLP‑1/GIP therapies.

• Mandatory generic substitution and lowest‑cost alternative pricing.

• Dispensing optimization for maintenance meds (90‑day supply; cap fees per script).

• Biosimilar first‑line/switch where clinically appropriate, with exception pathways.

Sources informing this section: Health Canada biosimilars fact sheet and handbook (interchangeability and switching); Ontario biosimilar policy bulletin (2024 update); TELUS Health Drug Data Trends & National Benchmarks (2024–2025).

Pooling and stop‑loss: thresholds to get right

• Fully insured (pooled) drug plans:

• EP3 (internal insurer pool): CLHIA/CDIPC standards require insurers to pool large recurring drug claims internally with thresholds below $50,000; pooled claims cannot be experience‑rated back to the group.

• Industry pooling (CDIPC): as a general rule, coverage applies when one member’s annual drug costs exceed about $65,000 for the first two years and about $32,500 thereafter, with 85% of eligible amounts shared up to a pooling cap. Plan sponsors still see trend and pooling charges in premiums.

• ASO (Administrative Services Only):

• Individual stop‑loss protection is essential for 15–30 lives. Common attachment points in Canada for groups this size range from $10,000 to $25,000 per member per year, and can be quoted higher or lower based on risk appetite. Select an attachment point that approximates 1–2% of payroll to balance volatility and premium.

Sources informing this section: CDIPC advisor materials and FAQ (EP3 and industry pool mechanics, typical thresholds); CLHIA commentary on EP3; Canadian ASO/stop‑loss issuers’ product guidance.

Dental: fee‑guide alignment and plan hygiene

• Reimburse at the current‑year provincial/territorial dental fee guide to avoid hidden drift; most 2025 fee‑guide increases are modest (e.g., ~2–4% in major provinces), down from 2023 peaks.

• Require predeterminations above set dollar thresholds and apply frequency limits (e.g., scaling units per 12 months) to control utilization without reducing access to preventive care.

Sources informing this section: Sun Life 2025 dental fee‑guide update; Western Compensation & Benefits Consultants trend summary; provincial dental association guidance.

ASO vs. fully insured (pooled): quick comparison

Note: Many groups blend—insured life/LTD, and either insured or ASO for health/dental.

Worked budget example (illustrative)

Company profile: 22 employees; average age 34; employer pays 100% of premiums; current plan is fully insured pooled (health + dental). Assumptions are illustrative—not a guarantee—and exclude taxes.

• Current annual cost: $285 per employee per month (health + dental) → $285 × 22 × 12 = $75,240.

• Without changes, 2025 pressure: assume +3.5% dental fee‑guide impact and +5% drug/EHC trend → blended +4.5% → projected $78,626.

• 90‑day redesign levers selected:

• Drug controls (mandatory generic + prior auth + biosimilar switch policy): modeled −3.0% vs. status quo.

• Maintenance‑med dispensing and fee caps: modeled −0.8%.

• Dental hygiene (current‑year fee guide + predeterminations): modeled −1.2% vs. projected.

• Pooling/stop‑loss optimization: no direct reduction to base claims; prevents shock at renewal.

• Modeled post‑redesign annual cost: $78,626 × (1 − 0.030 − 0.008 − 0.012) ≈ $74,753.

• Net effect vs. current: ≈ −$487 (−0.6%) despite underlying +4.5% trend; vs. “do nothing” 2025 projection: ≈ −$3,873 (−4.9%).

Interpretation: Modest design changes can offset most 2025 inflation for a 15–30‑employee group while preserving member experience. Larger savings are possible when migrating to ASO with the right stop‑loss and tight care management, but that introduces cash‑flow variability.

What Summit brings to a 90‑day reset

• Independent market access: we shop multiple carriers and funding methods without bias for better fit and value.

• Transparent compensation: see how we’re paid before you bind coverage; review How We Get Paid.

• Execution discipline: dedicated account management, templated RFPs, and quarterly utilization reviews.

• Fast start: talk to our benefits team to scope your 90‑day plan via Contact Summit.

Data and documents you’ll need on day 1

• Two years of experience reports with premium, paid claims, large‑claim detail, pooling charges, and IBNR (if applicable).

• Current contracts, booklets, and stop‑loss/EP3 riders (insured) or ASO agreements.

• Census with DOB, gender (where applicable), salaries (for life/LTD), class structure, waiting periods, and work status.

• Broker of Record (BOR) letter template if moving markets.

Source notes (select, 2023–2025)

• Health Canada, Biosimilar biologic drugs – Fact Sheet: definition of interchangeability and switching; statement that no meaningful differences are expected in efficacy/safety when switching within authorized indications (updated 2024).

• Health Canada, Handbook for healthcare professionals on biosimilars; and PMPRB/NPDUIS overview of provincial biosimilar transition policies (e.g., Ontario bulletin 240803, Aug. 22, 2024).

• TELUS Health, Drug Data Trends & National Benchmarks Reports (2024 and 2025 highlights): specialty share of private drug spend (~31% in 2023; ~33% in 2024) and category dynamics.

• Canadian Drug Insurance Pooling Corporation (CDIPC): advisor materials and FAQ describing EP3 standards, internal thresholds (<$50,000), industry pooling activation (general rule ~$65,000 first two years; ~$32,500 ongoing) and 85% sharing to pooling maximums.

• ASO/stop‑loss practice references (Canadian carriers/TPAs): common individual stop‑loss attachment points for small groups (often $10,000–$25,000 per member per year).

• Sun Life, 2025 Dental plan updates; Western Compensation & Benefits Consultants, Dental fee‑guide trends (2023–2025): most provinces show 2025 fee‑guide increases ~2–4%.

Disclaimer: All figures are illustrative. Benefits design, pricing, taxes, and legal requirements vary by insurer and jurisdiction. Summit provides brokerage and advisory services; this page is not tax or legal advice.